Skip to Content

Rydex Health Care H RYHAX

Medalist Rating as of | See Rydex Investment Hub
  • NAV / 1-Day Return 36.41  /  +0.33 %
  • Total Assets 22.2 Mil
  • Adj. Expense Ratio
    1.650%
  • Expense Ratio 1.650%
  • Distribution Fee Level High
  • Share Class Type No Load
  • Category Health
  • Investment Style Large Blend
  • Min. Initial Investment 2,500
  • Status Open
  • TTM Yield
  • Turnover 116%

USD | NAV as of Jul 19, 2024 | 1-Day Return as of Jul 19, 2024, 10:17 PM GMT+0

Morningstar’s Analysis RYHAX

Will RYHAX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Rydex Health Care H's Average Process Pillar and People Pillar ratings result in a Morningstar Medalist Rating of Neutral.

null Morningstar Manager Research

Morningstar Manager Research

Summary

Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the highest quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings RYHAX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 26.6
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Eli Lilly and Co

4.27 986,049
Healthcare

UnitedHealth Group Inc

3.44 793,087
Healthcare

Johnson & Johnson

2.89 666,468
Healthcare

Merck & Co Inc

2.85 656,825
Healthcare

AbbVie Inc

2.55 588,526
Healthcare

Thermo Fisher Scientific Inc

2.28 525,382
Healthcare

Amgen Inc

2.18 502,817
Healthcare

Danaher Corp

2.11 486,636
Healthcare

Pfizer Inc

2.10 484,755
Healthcare

Abbott Laboratories

1.93 446,264
Healthcare